Issei Komuro Selected Research

temocapril hydrochloride (temocapril)

2/2009	Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus.
4/2006	Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Issei Komuro Research Topics

Disease

151	Heart Failure 06/2022 - 06/2002
74	Myocardial Infarction 01/2022 - 06/2002
60	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 01/2002
36	Cardiomegaly (Heart Hypertrophy) 01/2021 - 01/2002
33	Fibrosis (Cirrhosis) 01/2022 - 01/2002
31	Atherosclerosis 01/2022 - 01/2002
30	Inflammation (Inflammations) 04/2021 - 09/2002
25	Hypertension (High Blood Pressure) 11/2021 - 12/2002
20	Neoplasms (Cancer) 08/2022 - 02/2002
20	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 09/2005
18	Myocardial Ischemia (Ischemic Heart Diseases) 01/2019 - 04/2002
17	Ischemia 07/2020 - 01/2003
17	Hypertrophy 04/2017 - 03/2002
16	Atrial Fibrillation 01/2022 - 09/2003
15	Cardiomyopathies (Cardiomyopathy) 02/2022 - 07/2002
15	Myocarditis (Carditis) 09/2020 - 09/2002
14	Diabetes Mellitus 01/2022 - 01/2004
13	Type 2 Diabetes Mellitus (MODY) 01/2022 - 04/2006
13	Pulmonary Arterial Hypertension 01/2022 - 12/2010
13	Pulmonary Hypertension 12/2021 - 06/2009
12	Hemorrhage 08/2022 - 06/2007
12	Thrombosis (Thrombus) 11/2021 - 04/2007
12	Hypoxia (Hypoxemia) 01/2019 - 01/2008
12	Infarction (Infarctions) 01/2017 - 08/2003
11	Diabetic Retinopathy (Retinopathy, Diabetic) 05/2022 - 08/2016
11	Heart Diseases (Heart Disease) 01/2021 - 12/2003
11	Ventricular Remodeling 07/2014 - 08/2003
9	Stroke (Strokes) 10/2022 - 01/2012
9	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2022 - 12/2009
9	Insulin Resistance 11/2013 - 01/2002
8	Left Ventricular Dysfunction 01/2022 - 03/2003
8	Chronic Renal Insufficiency 01/2021 - 04/2011
8	Death (Near-Death Experience) 01/2020 - 04/2009
8	Acute Coronary Syndrome 01/2020 - 02/2004
8	Marfan Syndrome (Marfan's Syndrome) 01/2020 - 07/2014
8	Abdominal Aortic Aneurysm 12/2019 - 01/2014
8	ST Elevation Myocardial Infarction 01/2019 - 09/2009
7	Hypercholesterolemia 05/2022 - 05/2013
7	Angina Pectoris 01/2022 - 07/2004
7	COVID-19 01/2022 - 09/2020
7	Hyperlipidemias (Hyperlipidemia) 08/2016 - 09/2010
6	Aortic Valve Stenosis (Aortic Stenosis) 09/2022 - 12/2012
6	Obesity 05/2022 - 09/2010
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 11/2021 - 01/2004
6	Pathologic Constriction (Stenosis) 01/2021 - 09/2003
6	Hypotension (Low Blood Pressure) 12/2020 - 07/2005
6	Neointima 12/2020 - 05/2006
6	Infections 10/2020 - 06/2007
6	Cardiac Arrhythmias (Arrythmia) 01/2020 - 06/2009
6	Loeys-Dietz Syndrome 11/2019 - 12/2015
6	Ventricular Tachycardia 05/2018 - 07/2002

Drug/Important Bio-Agent (IBA)

26	Angiotensin IIIBA 01/2022 - 03/2002
25	Proteins (Proteins, Gene)FDA Link 01/2019 - 06/2002
24	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022 - 08/2003
17	CytokinesIBA 01/2022 - 01/2003
16	LipidsIBA 10/2022 - 05/2006
16	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 12/2002
15	Antihypertensive Agents (Antihypertensives)IBA 08/2022 - 12/2003
15	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 03/2013 - 01/2003
14	Pharmaceutical PreparationsIBA 02/2022 - 12/2002
11	CalciumIBA 01/2020 - 07/2002
11	Angiotensin Receptor AntagonistsIBA 05/2016 - 07/2002
11	LigandsIBA 09/2014 - 01/2002
10	DiureticsIBA 01/2022 - 01/2013
10	oxidized low density lipoproteinIBA 12/2021 - 01/2010
10	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2011
10	Tolvaptan FDA Link 09/2019 - 01/2013
9	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2002
8	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2011
8	CholesterolIBA 01/2022 - 01/2012
8	SteroidsIBA 12/2021 - 09/2004
8	CreatinineIBA 09/2020 - 09/2009
8	Transcription Factors (Transcription Factor)IBA 09/2018 - 06/2002
8	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 12/2017 - 07/2002
8	PPAR gammaIBA 01/2010 - 01/2002
7	LDL CholesterolIBA 05/2022 - 01/2016
7	Adenosine Triphosphate (ATP)IBA 01/2019 - 08/2004
7	Eicosapentaenoic AcidIBA 01/2018 - 01/2013
7	Telmisartan (Micardis)FDA Link 03/2017 - 12/2010
6	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 08/2014
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 06/2007
6	C-Reactive ProteinIBA 01/2022 - 01/2013
6	Oxygen (Dioxygen)IBA 01/2021 - 06/2007
6	Phosphotransferases (Kinase)IBA 09/2020 - 07/2002
6	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2020 - 01/2013
6	Vasopressins (Vasopressin)IBA 09/2019 - 01/2013
6	SaltsIBA 12/2018 - 12/2002
6	EnzymesIBA 01/2015 - 07/2011
6	Anti-Arrhythmia AgentsIBA 04/2013 - 07/2002
6	candesartanIBA 01/2013 - 05/2004

Therapy/Procedure

103	Therapeutics 09/2022 - 07/2002
28	Percutaneous Coronary Intervention 11/2021 - 03/2003
20	Stents 01/2021 - 06/2002
18	Heart-Assist Devices 06/2022 - 01/2011
14	Heart Transplantation (Grafting, Heart) 06/2022 - 01/2012
12	Catheter Ablation 08/2022 - 09/2003
10	Cardiac Rehabilitation 03/2022 - 01/2017
7	Transcatheter Aortic Valve Replacement 09/2022 - 12/2012
7	Drug Therapy (Chemotherapy) 10/2020 - 06/2002
6	Cardiac Resynchronization Therapy 01/2021 - 01/2011